What is ImmunityBio, Inc.'s net income?

ImmunityBio, Inc. (IBRX) reported net income of -$632.8M in Q1 2026.

How has ImmunityBio, Inc.'s net income changed year-over-year?

ImmunityBio, Inc.'s net income decreased by 388.0% year-over-year, from -$129.67M to -$632.8M.

What is the long-term trend for ImmunityBio, Inc.'s net income?

Over 4 years (2021 to 2025), ImmunityBio, Inc.'s net income has grown at a 0.1% compound annual growth rate (CAGR), from -$349.85M to -$351.47M.

What does net income mean?

Net income as the starting point for the indirect method operating cash flow reconciliation.

ImmunityBio, Inc. IBRX Net Income

Net Income at other companies

Bristol-Myers SquibbBMY

$2.68B+8.8%

Johnson & JohnsonJNJ

$5.24B-52.4%

Merck & Co.MRK

-$4.24B-183%

Gilead SciencesGILD

$2.02B+53.7%

Immunovant, Inc.IMVT

——

Kymera TherapeuticsKYMR

——

Segments

By segment

See full

Reportable Segment-$632.8M-388%

Other financials

Income statement

See full

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

See full

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s net income?: ImmunityBio, Inc. (IBRX) reported net income of -$632.8M in Q1 2026.
How has ImmunityBio, Inc.'s net income changed year-over-year?: ImmunityBio, Inc.'s net income decreased by 388.0% year-over-year, from -$129.67M to -$632.8M.
What is the long-term trend for ImmunityBio, Inc.'s net income?: Over 4 years (2021 to 2025), ImmunityBio, Inc.'s net income has grown at a 0.1% compound annual growth rate (CAGR), from -$349.85M to -$351.47M.
What does net income mean?: Net income as the starting point for the indirect method operating cash flow reconciliation.